-
Published 9/26/2026
Kawtharany H, Mahmoud N, Rayyan A, Ghazal M, Dasgupta N, Sarswat N, Sanchorawala V, Jamal F. Efficacy and safety of ACEi, ARB, and ARNi in cardiac amyloidosis: A retrospective propensity score-matched cohort study. Curr Probl Cardiol. 2026 Sep 26; 52(1):103458. PMID: 42800493.
-
Published 8/28/2026
Huda N, Spencer B, Hicks CW, Jayaraman S, Pantelopulos GA, Wong S, Chen H, Best RB, Sanchorawala V, Lavatelli F, Prokaeva T, Gursky O. Cryo-EM reveals patient- versus organ-specific structural diversity and bound ligands in ?6 light chain amyloids. bioRxiv. 2026 Aug 28. PMID: 42760916.
-
Published 8/27/2026
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Mollee P, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Bhutani M, Beksac M, Libby E, Valent J, Hungria V, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Tran N, Wang J, Chen Y, Vasey SY, Schecter JM, Vermeulen J, Comenzo RL, Merlini G. Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis. Blood. 2026 Aug 27; 148(9):1097-1107. PMID: 42118698.
-
Published 8/11/2026
Azzam M, Hamarsha Q, Kawtharany H, Nazzal J, Alkhader A, Khraise T, AlMasri MM, Abou Zeid HK, Alwan I, Jaber N, Seftel MD, Aguirre MA, Boedicker D, Bumma N, Carroll A, Comenzo R, Cook J, Dasgupta N, De La Torre AH, Dispenzieri A, Jamal F, Khouri J, Picken MM, Raza S, Leung N, Sanchorawala V, Sarswat N, Shaikh H, Singh D, Kukreti V, Mustafa RA. Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis. Blood Adv. 2026 Aug 11; 10(15):5293-5307. PMID: 41979328.
-
Published 8/3/2026
Wechalekar AD, Dispenzieri A, Sanchorawala V, Kastritis E, Bhutani D, Bianchi G, Jimenez-Zepeda VH, Suzuki K, Lentzsch S, Huart A, Carpinteiro A, Swenson ES, Khan Z, Catini J, Kulkarni H, Meltzer B, Lake S, Liedtke M. Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials. J Clin Oncol. 2026 Sep 10; 44(26):2563. PMID: 42546230.